Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Maintenance Therapy for Metastatic CRC

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRC

April 7th 2021

Atrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.

FDA Approves New Cetuximab Dose in KRAS Wild-Type, EGFR-Expressing CRC, Head and Neck Cancer

April 7th 2021

The FDA has approved a new biweekly dosing regimen of 500 mg/m2 as a 120-minute intravenous infusion for cetuximab (Erbitux) for patients with KRAS wild-type, EGFR-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

Dr. Dasari on Eligibility Criteria for the FRESCO-2 trial With Fruquintinib in CRC

April 5th 2021

Nageshwara Arvind Dasari, MD, discusses the eligibility criteria for the phase 3 FRESCO-2 trial, which examined the use of fruquintinib in patients with metastatic colorectal cancer.

ctDNA Scratches the Surface in Colorectal Cancer

April 5th 2021

Axel Grothey, MD, discusses the potential applications for ctDNA in CRC and shed light on the updated analysis from the pivotal IMbrave150 trial in advanced hepatocellular carcinoma.

Dr. Philip Spotlights Ongoing Research Efforts in CRC

April 2nd 2021

Tony Philip, MD, discusses research efforts underway in colorectal cancer.

DNX-2440 Shows Promise in CRC and Other Cancers With Liver Metastasis as Phase 1 Trial Begins

April 2nd 2021

Investigation into a novel oncolytic adenovirus as a treatment option for patients with colorectal cancer and other cancers with liver metastasis is underway.

Applying Aggressive Therapy to Treat mCRC Up Front

April 2nd 2021

The rationale for treating select patients with metastatic colorectal cancer with intensive therapy in the first-line setting vs waiting until disease progression.

Colorectal Cancer in a Younger Population

April 2nd 2021

Cathy Eng, MD, FACP, FASCO, of Vanderbilt-Ingram Cancer Center reacts to the increasing rate of colorectal cancer among the younger population and highlights topics that apply specifically to counseling younger patients.

Dr. Eng on the Rising Incidence of Early-Onset CRC

April 1st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rising incidence of early-onset colorectal cancer.

Noninvasive cfDNA Blood Test for Advanced Adenoma and CRC Under Exploration

March 31st 2021

A prospective, multicenter, observational USOPTIVAL study has been initiated in the United States to examine an investigational cell-free DNA blood test to detect advanced adenoma and colorectal cancer.

Dr. Grothey on the Differences Between Available ctDNA Assays in CRC

March 29th 2021

Axel Grothey, MD, discusses the differences between available assays evaluating circulating tumor DNA in colorectal cancer.

Dr. Bekaii-Saab on the Challenges of Utilizing Chemotherapy-Free Regimens in CRC

March 25th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

Optimizing mCRC Treatment: Decision-Making With Patients

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.

FDA Grants 2 Breakthrough Device Designations to Signatera MRD Test

March 24th 2021

The FDA has granted 2 breakthrough device designations to cover new intended uses of the Signatera molecular residual disease test developed by Natera, Inc.

Messersmith Makes Sense of the Novel Approaches on the Rise in GI Malignancies

March 23rd 2021

The pipeline of new agents in gastrointestinal cancers is robust, with the emergence of several antibody-drug conjugates, KRAS G12C inhibitors, and novel TKI/immune checkpoint inhibitor combinations.

Dr. Eng Discusses the Ongoing FRESCO-2 Trial in mCRC

March 23rd 2021

Cathy Eng, MD, FACP, FASCO, discusses the ongoing phase 3 FRESCO-2 trial in metastatic colorectal cancer.

ctDNA Possesses the Potential to Revolutionize Care in CRC and Beyond

March 23rd 2021

Circulating tumor DNA is working to transform care in colorectal cancer and beyond and positivity is actionable at this time.

Dr. Basu-Mallick on the Importance of Clinical Research Examining ctDNA in CRC

March 22nd 2021

Atrayee Basu-Mallick, MD, discusses the importance of clinical research examining the role of circulating tumor DNA in patients with colorectal cancer.